Mineralys Therapeutics Inc expected to post a loss of 72 cents a share - Earnings Preview

Mineralys Therapeutics

08/08/2025 23:08

Mineralys Therapeutics Inc MLYS.OQ MLYS.O is expected to  show no change in quarterly revenue when it reports  results on August 12 for the period ending June 30 2025

​LSEG's mean analyst estimate for Mineralys Therapeutics Inc is for a loss of 72 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Mineralys Therapeutics Inc is $40.00, about 67.8% above its last closing price of $12.87

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATEÂŪ
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2025
-0.92
-0.98
-0.79
Beat
19.6
Dec. 31 2025
-1.11
-1.08
-0.98
Beat
9
Sep. 30 2024
-0.87
-0.83
-1.13
Missed
-35.4​
Jun. 30 2024
-0.70
-0.70
-0.83
Missed
-18.6
​​Mar. 31 2024
-0.61
-0.67
-0.70
Missed
-4.8
Dec. 31 2023
-0.82
-0.61
Beat
26.1​
Sep. 30 2023
-0.70
-0.76
-0.57
Beat
25
Jun. 30 2023
-0.67
-0.72
-0.31
Beat
56.9

This summary was machine generated August 8 at 22:08 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)